Actionable news
All posts from Actionable news
Actionable news in IMGN: ImmunoGen, Inc.,

ImmunoGen earns $10M milestone from Bayer related to ADC technology

In a regulatory filing, ImmunoGen (NASDAQ:IMGN) reports that it has earned a $10M milestone payment from Bayer (OTCPK:BAYRY) triggered by the initiation of a Phase 2 clinical trial assessing anetumab ravtansine (BAY 94-9343) in a type of mesothelioma.

Anetumab ravtansine is an anticancer...